Navigation Links
ev3 Inc. to Report 2007 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 22, 2008
Date:2/8/2008

PLYMOUTH, Minn., Feb. 8 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV) will release its 2007 fourth quarter and full-year financial results on Friday, February 22, 2008, before regular market trading hours.

The company will host a conference call and webcast the same day at 7:30 a.m. CT (8:30 a.m. ET). ev3 management will review its fourth quarter and full-year financial and operating results and future outlook, followed by a question and answer session.

The conference call will be available to interested parties through a live audio webcast at http://www.ev3.net, where it will be archived and accessible for approximately 90 days. The live dial-in number for the call is 800-901-5231 (U.S.) or 617-786-2961 (International). The participant passcode is 91202727.

If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial 888-286-8010 (U.S.) or 617-801-6888 (International) and enter passcode 63034695. The audio replay will be available beginning at 10:00 a.m. CT on Friday, February 22, 2008 until Friday, February 29, 2008.

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to improving the lives of patients with vascular disease through the development of innovative endovascular therapies. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolic coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.

ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.

CONTACT INFORMATION:

INVESTORS and MEDIA

Julie Tracy

Sr. Vice President, Chief Communications Officer

ev3 Inc.

office: (949) 680-1375

jtracy@ev3.net


'/>"/>
SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for ... time. So which eye do you rinse first if a dangerous substance enters both eyes? ... Eye Wash with its unique dual eye piece. , “Whether its dirt and debris, ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):